Chiva Pharma Acquires Global Rights to Osteoporosis Drug from Ligand
October 11, 2011 at 06:33 AM EDT
Chiva Pharma of China paid $4 million for global rights to an osteoporosis drug developed by Ligand Pharma (NSDQ: LGND ). Fablyn is a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women. Chiva was selected as one of two “Most Promising” companies at last month’s BioBay Investor Forum, which was organized by ChinaBio®, More details.... Stock Symbol: (NSDQ: LGND) Share this with colleagues:
